The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
A CDC vaccine advisory committee meeting scheduled for next week has been postponed. It was the first vaccine meeting since ...
A panel of experts advising the U.S. Centers for Disease Control and Prevention on vaccines will not convene for its February ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...